Recurrent Endometrial Cancer
14
2
2
4
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
4 terminated out of 14 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
ALPINE: Maintenance Letrozole/Abemaciclib
Study of ART0380 in Patients With Biologically Selected Solid Tumors
Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma